Acyclic Hydrazides as Cannabinoid Receptor Modulators
    3.
    发明申请
    Acyclic Hydrazides as Cannabinoid Receptor Modulators 审中-公开
    非环状酰肼作为大麻素受体调节剂

    公开(公告)号:US20080076805A1

    公开(公告)日:2008-03-27

    申请号:US11661834

    申请日:2005-10-03

    申请人: Linus Lin Ping Liu

    发明人: Linus Lin Ping Liu

    摘要: The acyclic hydrazides of the invention are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders (including smoking cessation), the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

    摘要翻译: 本发明的无环酰肼是大麻素-1(CB1)受体的拮抗剂和/或反向激动剂,可用于治疗,预防和抑制由CB1受体介导的疾病。 本发明的化合物可用作治疗精神病,记忆缺陷,认知障碍,偏头痛,神经病,包括多发性硬化和神经 - 巴利综合征的神经炎症性疾病以及病毒性脑炎的炎症性后遗症,脑血管 事故和头部创伤,焦虑症,压力,癫痫,帕金森病,运动障碍和精神分裂症。 这些化合物还可用于治疗药物滥用障碍(包括戒烟),治疗肥胖或进食障碍,以及治疗哮喘,便秘,慢性肠假性梗阻和肝硬化。

    Substituted amides
    5.
    发明申请

    公开(公告)号:US20060106071A1

    公开(公告)日:2006-05-18

    申请号:US10538395

    申请日:2003-12-15

    摘要: Novel compounds of the structural formula (I) are antagonists and/or inverse agonists of the Cannabinoid-1 (CB1) receptor and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory deficits, cognitive disorders, migraine, neuropathy, neuro-inflammatory disorders including multiple sclerosis and Guillain-Barre syndrome and the inflammatory sequelae of viral encephalitis, cerebral vascular accidents, and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders, and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of obesity or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction, and cirrhosis of the liver.

    Compressed far-sighted eyeglasses within a case
    6.
    发明授权
    Compressed far-sighted eyeglasses within a case 有权
    在一个案件中压缩有远见的眼镜

    公开(公告)号:US6053309A

    公开(公告)日:2000-04-25

    申请号:US246357

    申请日:1999-02-08

    申请人: Linus Lin

    发明人: Linus Lin

    IPC分类号: A45C11/04

    CPC分类号: A45C11/04

    摘要: A pair of far-sighted eyeglasses with a case includes a case consisting of an upper half case and a lower half case, and a pair of far-sighted eyeglasses. The eyeglasses have two elastic temples with curved portions that protrude slightly beyond an upper edge of the lower half case when placed in the case such that the temples are compressed by the upper half case when the case is closed. When the upper half case is disengaged from the lower half case for opening, the upper half case is pushed away from the lower half case by the temples recovering the elasticity of the curved portions so as to facilitate the opening of the case, without the possibility of the eyeglasses falling out of the case during opening.

    摘要翻译: 具有外壳的一副具有远见的眼镜包括由上半壳和下半壳组成的壳体以及一对有远见的眼镜。 眼镜具有两个弹性体,其弯曲部分在放置在壳体中时稍微突出于下半壳体的上边缘,使得当壳体关闭时,这些镜腿被上半部分压缩。 当上半壳与用于打开的下半壳脱开时,上半壳被恢复弯曲部分的弹性的寺庙从下半壳推开,以便于壳体的打开,而不会有可能 的眼镜在打开期间脱离外壳。